Biogen takes Creative Biolabs to court over antibody
19-03-2020
Biogen fights off Mylan’s Tecfidera patent challenge
06-02-2020
Winui / Shutterstock.com
In the high stakes world of life sciences, the strength of a company’s IP portfolio can determine the value of a corporate transaction, argue Jonathan Harris and Nisan Zaghi of Axinn, and Ian Lodovice of Biogen.
Comprehensive and effective IP due diligence in life science transactions is essential. This is especially true of emerging and growth life science companies, where a single asset protected by strong IP can command hundreds of millions of dollars.
Such IP due diligence not only requires a deep understanding of technology and business goals, but also a working knowledge of key case law governing IP ownership, protection and infringement.
Some of this case law is obscure, but it can affect the IP due diligence analysis in unexpected and significant ways. Below are five key legal principles every IP due diligence lawyer in life sciences should know.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
due diligence, life sciences, prior art, SEC filings, Eli Lilly, Biogen, Federal Circuit, doctrine of equivalents
